Navigation Links
Two New Studies in the British Medical Journal Find That Bayer's Yaz and Yasmin Birth Control Pills Have an Increased Risk of Blood Clot
Date:4/22/2011

PHILADELPHIA, April 22, 2011 /PRNewswire-USNewswire/ -- The following release is being issued by law firms RodaNast, P.C.; Levin, Fishbein, Sedran & Berman and Feldman & Pinto:

According to two new studies published in the online edition of the British Medical Journal, Bayer's birth control pills Yaz and Yasmin, containing a new progestin drospirenone (DSRP), carry up to triple the risk of serious blood clots (known as venous thromboembolism) over traditional pills containing the progestin levonorgestrel (LNG).

Approximately 2,000 lawsuits have been filed in Pennsylvania before Philadelphia Court of Common Pleas Judge Sandra Mazer Moss, Coordinating Judge of the Complex Litigation Center.  Another 4,000 lawsuits are pending in federal court before the Judge David R. Herndon, who is overseeing the federal multidistrict litigation (MDL).  The lawsuits allege that Yaz and Yasmin have risks beyond those of traditional birth control pills and that Bayer over-promoted the drug without disclosing the higher risks. Bayer was warned by the Food and Drug Administration (FDA), in the fall of 2008, that Bayer's television advertisements were misleading and did not disclose the additional risks.

The findings of the new studies provide additional evidence that the older oral contraceptives "appear to be a safer choice with regard to venous thromboembolism than preparations containing drospirenone," says Dr. Susan Jick of Boston University's School of Medicine, who led the research team.

Judge Moss appointed three Pennsylvania lawyers as Liaison Counsel for the plaintiffs, including Michael M. Weinkowitz of Levin, Fishbein, Sedran & Berman, Philadelphia, Daniel N. Gallucci of RodaNast, P.C., Lancaster, and Rosemary Pinto of Feldman & Pinto, Philadelphia.  Dianne M. Nast, RodaNast, P.C. was appointed Pennsylvania Federal-State Liaison Counsel by the Honorable David Herndon.


'/>"/>
SOURCE RodaNast, P.C.; Levin, Fishbein, Sedran & Berman; Feldman & Pinto
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Cetero Research Seminars Provide Insights on Designing Accelerated Proof-of-Concept Studies
2. ConvaTec Supported Studies to be Presented at the 24th Annual Symposium on Advanced Wound Care (SAWC) and Wound Healing Society (WHS)
3. New Clinical Studies Reinforce the LAP-BAND® System is a Safe and Effective Weight-Loss Treatment for Obese Adults with Obesity-Related Comorbid Conditions
4. MAP Pharmaceuticals to Present Data From LEVADEX® Pharmacokinetics and Pharmacodynamics Safety Studies at the 63rd Annual Meeting of the American Academy of Neurology
5. Preclinical Studies in Pancreatic Cancer and Melanoma Demonstrated ADI-PEG 20 Works Synergistically With Inhibitors of Autophagy
6. Three Studies Presented at the 2011 SHEA Annual Scientific Meeting Show That the ICU Medical MicroCLAVE® Contributes to a Significant Decrease in Bacterial Transfer and Reduction in Bloodstream Infections
7. New Studies Show Clinical Advantages of Masimo Noninvasive Hemoglobin, PVI, and Perfusion Index in Critically-ill Patients
8. BioTox Sciences (BTS) Deploys eStudy™ Hosted Solution for Management of GLP & Non-GLP Preclinical Studies
9. Auxilium Pharmaceuticals, Inc. Completes Enrollment of XIAFLEX® Phase III Double-Blind Studies for Peyronies Disease
10. FDA Clears Palatin Technologies IND Filing to Commence Clinical Studies for Asthma
11. Women Get Short Shrift in Many Heart Device Studies, Despite Requirement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... March 22, 2017 AMRI , a ... been working with the life sciences industry to improve ... 25 years, has been recognized for its excellence as ... as part of the Life Science Leader,s 2017 ... expertise, quality and reliability. "Competing with ...
(Date:3/22/2017)... STOCKHOLM , March 22, 2017 ... biopharmaceutical company developing novel anticancer therapies targeting the ... with Memorial Sloan Kettering Cancer Center to study ... p53 by APR-246. The goal of ... efficacy of APR-246 in combination with multiple other ...
(Date:3/22/2017)... Research and Markets has announced the addition of the "Global ... ... market to grow at a CAGR of 14.58% during the period ... been prepared based on an in-depth market analysis with inputs from ... prospects over the coming years. The report also includes a discussion ...
Breaking Medicine Technology:
(Date:3/22/2017)... ... March 22, 2017 , ... Last year, 43 million ... US Department of Agriculture report. While excess dairy can be caused by several ... Lactose sensitivity is the inability to properly digest lactose, a sugar found in milk ...
(Date:3/22/2017)... Park Ridge, NJ (PRWEB) , ... March 22, ... ... financial planning firm that serves communities throughout north Jersey and the New York ... Bergen County to provide regional support for homeless families. , At present, more ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Vanderbeck Agency, a Long ... Nassau County region, is embarking on a combined charity effort with the Great Neck ... the last 25 years, the Great Neck Breast Cancer Coalition has worked to support ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... services to regional families and business owners, is joining the Teen Recovery Solutions ... in the area. , A growing number of Oklahoma teens and adolescents face ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Zabbia Insurance Agency, a ... and business owners in the greater Nassau County area, is embarking on a ... Every 3 minutes, someone in America is diagnosed with blood cancer. Every 9 ...
Breaking Medicine News(10 mins):